Evidence map›Paper›PMID 30909615›Full record

ReviewInternational journal of molecular sciences2019

Psoriasis Pathogenesis and Treatment.

Adriana Rendon, Knut Schäkel

2 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 912 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
912citing papers in PubMed, 7 pooled it
60.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04250792 phase1completednot on this map

Efficacy of Low Dose Naltrexone in Psoriasis; Clinical Trial in a Tertiary Care Hospital of Karachi.

TypeinterventionalSponsorJinnah Postgraduate Medical CentreRan2019 to 2019Enrolled42ConditionsPsoriasisArmsNaltrexone Pill
NCT05105139 completednot on this mapstarted 2021, after this paper: background citation

Retrospective Study to Evaluate the Safety of Sebryl® and / or Sebryl Plus® in the Treatment of Seborrheic Dermatitis and Psoriasis of the Scalp in Routine Medical Practice.

TypeobservationalSponsorLaboratorios Silanes S.A. de C.V.Ran2021 to 2022Enrolled90ConditionsSeborrheic Dermatitis, Psoriasis of ScalpArmsAllantoin/ Coal Tar/ Clioquinol, Allantoin/ Coal Tar/ Clioquinol/ Triclosan
3 · Its place in the literature

Who cites it

912 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,924 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. A phase IIb single-center study to assess the efficacy of apremilast for the treatment of nummular eczema.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Trial
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

852 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Adriana RendonDepartment of Dermatology, Heidelberg University, 69120 Heidelberg, Germany. RuthAdriana.RendonMedina@med.uni-heidelberg.de.
Knut SchäkelDepartment of Dermatology, Heidelberg University, 69120 Heidelberg, Germany. Knut.Schaekel@med.uni-heidelberg.de.
Heidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research on psoriasis pathogenesis has largely increased knowledge on skin biology in general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of psoriasis have been translated into targeted and highly effective therapies providing fundamental insights into the pathogenesis of chronic inflammatory diseases with a dominant IL-23/Th17 axis. This review discusses the mechanisms involved in the initiation and development of the disease, as well as the therapeutic options that have arisen from the dissection of the inflammatory psoriatic pathways. Our discussion begins by addressing the inflammatory pathways and key cell types initiating and perpetuating psoriatic inflammation. Next, we describe the role of genetics, associated epigenetic mechanisms, and the interaction of the skin flora in the pathophysiology of psoriasis. Finally, we include a comprehensive review of well-established widely available therapies and novel targeted drugs.

Indexed as

AnimalsChronic DiseaseDiagnosis, DifferentialDisease SusceptibilityHumansPsoriasisSkinSymptom Assessmentchronic skin diseaseinflammationpsoriasis

Identifiers

PMID30909615
PMCPMC6471628
OpenAlexW2924895007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.